Additionally, in mouse models of breast and pancreatic neuroendocrine tumors, TLSs were shown to be therapeutically induced and associated with tumor control; anti-angiogenic therapy plus PD-L1 blockade could modulate the angiogenic vasculature, induce TLSs, and enhanced cytotoxic T-cell activity, with ensuing survival benefits (159, 160). This evidence concerns the gene CD274 and neoplasm.